Trinity Biotech plc Cash Flow Conversion Efficiency
Trinity Biotech plc cash flow conversion efficiency. Based on the latest financial reports, Trinity Biotech plc (TRIB) has a cash flow conversion efficiency ratio of 0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.55 Million) by net assets ($-71.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Trinity Biotech plc (1993–2025)
Cash flow conversion efficiency of Trinity Biotech plc from 1993 to 2025. This chart illustrates how Trinity Biotech plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Trinity Biotech plc (TRIB) share price today for real-time trading data and today's change.
Trinity Biotech plc Cash Flow Conversion Ratio Explained
Trinity Biotech plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Trinity Biotech plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trinity Biotech plc ranked by their cash flow conversion efficiency. Also see how much is Trinity Biotech plc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Artemis Resources Ltd
AU:ARV
|
-0.059x |
|
Nacon S.A.
PA:NACON
|
-0.139x |
|
Instinct Bio Technical Company Holdings Inc. Ordinary Shares
NASDAQ:BIOT
|
N/A |
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
-0.436x |
|
Zephyr Minerals Ltd
V:ZFR
|
0.006x |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
0.049x |
|
Industronics Bhd
KLSE:9393
|
-0.423x |
|
Game Your Game, Inc. Common Stock
NASDAQ:GYGY
|
0.160x |
Annual Cash Flow Conversion Efficiency for Trinity Biotech plc (1993–2025)
The table below shows the annual cash flow conversion efficiency of Trinity Biotech plc from 1993 to 2025. Review Trinity Biotech plc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-71.98 Million | $-5.93 Million | 0.082x | -30.86% |
| 2024-12-31 | $-35.18 Million | $-4.19 Million | 0.119x | -75.31% |
| 2023-12-31 | $-23.95 Million | $-11.56 Million | 0.483x | +14.01% |
| 2022-12-31 | $-2.18 Million | $-921.00K | 0.423x | +101.02% |
| 2021-12-31 | $-319.00K | $13.24 Million | -41.498x | -287.64% |
| 2020-12-31 | $-2.22 Million | $23.75 Million | -10.705x | -1021.70% |
| 2019-12-31 | $4.71 Million | $5.47 Million | 1.161x | +637.81% |
| 2018-12-31 | $44.05 Million | $6.93 Million | 0.157x | -15.26% |
| 2017-12-31 | $65.20 Million | $12.11 Million | 0.186x | +46.68% |
| 2016-12-31 | $108.73 Million | $13.77 Million | 0.127x | +119.62% |
| 2015-12-31 | $213.89 Million | $12.34 Million | 0.058x | -27.88% |
| 2014-12-31 | $196.97 Million | $15.75 Million | 0.080x | +25.02% |
| 2013-12-31 | $183.01 Million | $11.71 Million | 0.064x | -45.98% |
| 2012-12-31 | $169.38 Million | $20.06 Million | 0.118x | -12.52% |
| 2011-12-31 | $151.33 Million | $20.48 Million | 0.135x | -17.11% |
| 2010-12-31 | $141.29 Million | $23.07 Million | 0.163x | -12.05% |
| 2009-12-31 | $79.34 Million | $14.73 Million | 0.186x | +14.05% |
| 2008-12-31 | $65.91 Million | $10.73 Million | 0.163x | +45.14% |
| 2007-12-31 | $136.84 Million | $15.35 Million | 0.112x | +154.62% |
| 2006-12-31 | $167.26 Million | $7.37 Million | 0.044x | -36.08% |
| 2005-12-31 | $133.62 Million | $9.21 Million | 0.069x | +18957.79% |
| 2004-12-31 | $116.14 Million | $42.00K | 0.000x | -99.19% |
| 2003-12-31 | $80.26 Million | $3.60 Million | 0.045x | -75.75% |
| 2002-12-31 | $62.91 Million | $11.65 Million | 0.185x | +106.90% |
| 2001-12-31 | $56.53 Million | $5.06 Million | 0.090x | +63.09% |
| 2000-12-31 | $55.04 Million | $3.02 Million | 0.055x | -67.36% |
| 1999-12-31 | $22.72 Million | $3.82 Million | 0.168x | +345.55% |
| 1998-12-31 | $14.60 Million | $-1.00 Million | -0.068x | +65.26% |
| 1997-12-31 | $7.10 Million | $-1.40 Million | -0.197x | +41.94% |
| 1996-12-31 | $10.60 Million | $-3.60 Million | -0.340x | -218.40% |
| 1995-12-31 | $7.50 Million | $-800.00K | -0.107x | +95.53% |
| 1994-12-31 | $1.30 Million | $-3.10 Million | -2.385x | -208.01% |
| 1993-12-31 | $3.10 Million | $-2.40 Million | -0.774x | -- |
About Trinity Biotech plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually tr… Read more